

Special Issue

NASH and Systemic Complications: From Basic to Clinical Research

Message from the Guest Editors

Dear colleagues, High intake of sugar- and fat-enriched meals and low physical activity has led to an increase in NAFLD both in adults and in children. Whereas most of the patients develop simple fat accumulation, up to one-third is also affected with inflammation in the liver (NASH). NASH is considered a global health threat. However, the gold standard for diagnosing NASH is an invasive liver biopsy and therapeutic options to cure NASH do not exist, implying the urgent need for better understanding its underlying mechanisms. This Special Issue intends to shed light on the pathophysiology, clinical problems, diagnostic methods, therapeutic approaches and lifestyle adaptations of NASH as well as on its systemic effects, including cardiovascular diseases, type 2 diabetes, cancer and chronic kidney disease. Our overall aim is to create awareness of the opportunities and challenges in translational NASH and to the fact that NASH patients can benefit from a multidisciplinary evaluation. We encourage all researchers and clinicians in these fields to share their novel findings, interpretations and ideas. Dr. Yvonne Oligschläger

Guest Editors

Prof. Dr. Ronit Shiri-Sverdlov
NUTRIM, Department of Molecular Genetics, Maastricht University,
Maastricht, The Netherlands

Dr. Sabine Baumgartner
Department of Nutrition and Movement Sciences, Maastricht
University, Maastricht, The Netherlands

Deadline for manuscript submissions

closed (31 January 2021)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/21069

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).